Financial News

Financial Report: Merck

Revenues up 8% in the quarter

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck
1Q Revenues: $10.8 billion (+ 8%)
1Q Earnings: $2.9 billion (earnings were $736 million 1Q18)
Comments: Keytruda sales were $2.3 billion in the quarter, up 55%. JANUVIA sales were down 5% to $1.4 billion due to continuing pricing pressure in the U.S. Growth in the quarter was partially offset by the ongoing impacts from the loss of market exclusivity for ZETIA and VYTORIN with sales down 50% to $238 million. Growth in vaccines was driven largely by GARDASIL, with sales of $838 million, up 27%. VARIVAX sales were up 27% to $496 million. BRIDION, for the reversal of neuromuscular blockade, had sales of $255 million, up 25%. International sales represented 58% of total sales in the quarter led by China, which had sales growth of 58%, driven by vaccines and oncology.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters